Dahish Ajarim

3.2k total citations · 1 hit paper
88 papers, 2.4k citations indexed

About

Dahish Ajarim is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Dahish Ajarim has authored 88 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 30 papers in Cancer Research and 22 papers in Pathology and Forensic Medicine. Recurrent topics in Dahish Ajarim's work include Breast Cancer Treatment Studies (20 papers), Lymphoma Diagnosis and Treatment (11 papers) and Cancer Treatment and Pharmacology (11 papers). Dahish Ajarim is often cited by papers focused on Breast Cancer Treatment Studies (20 papers), Lymphoma Diagnosis and Treatment (11 papers) and Cancer Treatment and Pharmacology (11 papers). Dahish Ajarim collaborates with scholars based in Saudi Arabia, Egypt and United States. Dahish Ajarim's co-authors include Asma Tulbah, Taher Al‐Tweigeri, Hazem Ghebeh, Said Dermime, Naser Elkum, Mohamed Alshabanah, Fouad Al‐Dayel, Khawla S. Al‐Kuraya, Adnan Ezzat and Ghofran Al-Qudaihi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Dahish Ajarim

86 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic Factors

2006 504 citations Hazem Ghebeh, Mohamed Alshabanah et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dahish Ajarim Saudi Arabia	26	1.4k	609	552	527	421	88	2.4k
Faye Elliott United Kingdom	22	1.4k 1.1×	753 1.2×	739 1.3×	386 0.7×	194 0.5×	56	2.4k
Björn Nodin Sweden	32	1.5k 1.1×	1.0k 1.7×	488 0.9×	594 1.1×	612 1.5×	118	2.8k
Deolinda Pereira Portugal	26	1.3k 1.0×	937 1.5×	446 0.8×	514 1.0×	274 0.7×	86	2.8k
Matthew Boente United States	24	1.5k 1.1×	902 1.5×	485 0.9×	464 0.9×	351 0.8×	54	3.7k
Ioannis A. Voutsadakis Canada	27	1.2k 0.9×	914 1.5×	298 0.5×	639 1.2×	187 0.4×	161	2.3k
Thaer Khoury United States	32	1.5k 1.1×	1.1k 1.7×	675 1.2×	1.1k 2.0×	273 0.6×	153	3.1k
Volker Möbus Germany	26	1.2k 0.9×	493 0.8×	227 0.4×	587 1.1×	276 0.7×	117	2.2k
Dusan Kotasek Australia	28	1.2k 0.9×	448 0.7×	371 0.7×	282 0.5×	227 0.5×	104	2.3k
Taher Al‐Tweigeri Saudi Arabia	24	1.7k 1.3×	619 1.0×	204 0.4×	553 1.0×	729 1.7×	61	2.5k
Seung‐Sook Lee South Korea	32	1.1k 0.8×	641 1.1×	947 1.7×	326 0.6×	339 0.8×	142	2.8k

Countries citing papers authored by Dahish Ajarim

Since Specialization

Citations

This map shows the geographic impact of Dahish Ajarim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dahish Ajarim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dahish Ajarim more than expected).

Fields of papers citing papers by Dahish Ajarim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dahish Ajarim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dahish Ajarim. The network helps show where Dahish Ajarim may publish in the future.

Co-authorship network of co-authors of Dahish Ajarim

This figure shows the co-authorship network connecting the top 25 collaborators of Dahish Ajarim. A scholar is included among the top collaborators of Dahish Ajarim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dahish Ajarim. Dahish Ajarim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Al‐Tweigeri, Taher, et al.. (2021). Impact of Pathologic Complete Response following Neoadjuvant Chemotherapy ± Trastuzumab in Locally Advanced Breast Cancer. Journal of Oncology. 2021. 1–10. 5 indexed citations

Ghebeh, Hazem, Adher Alsayed, Riham Eiada, et al.. (2021). Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer. Scientific Reports. 11(1). 19154–19154. 18 indexed citations

Ajarim, Dahish, et al.. (2020). Trastuzumab, Pertuzumab, and Docetaxel as the First Line for HER-2-Positive Metastatic Breast Cancer among Arabs. Breast Care. 16(1). 59–65. 1 indexed citations

Ajarim, Dahish, et al.. (2019). Behavior and Outcomes of Pregnancy Associated Breast Cancer. Asian Pacific Journal of Cancer Prevention. 20(1). 135–138. 9 indexed citations

Al‐Tweigeri, Taher, et al.. (2015). A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin–docetaxel with or without trastuzumab in locally advanced breast cancer. Cancer Chemotherapy and Pharmacology. 77(1). 147–153. 14 indexed citations

Beg, Shaham, Abdul K. Siraj, Sarita Prabhakaran, et al.. (2015). Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer. Breast Cancer Research and Treatment. 151(3). 541–553. 44 indexed citations

Çolak, Dilek, Albandary AlBakheet, Abdelmoneim Eldali, et al.. (2013). Age-Specific Gene Expression Signatures for Breast Tumors and Cross-Species Conserved Potential Cancer Progression Markers in Young Women. PLoS ONE. 8(5). e63204–e63204. 101 indexed citations

Uddin, Shahab, Azhar R. Hussain, Maqbool Ahmed, et al.. (2010). Inhibition of Fatty Acid Synthase Suppresses c-Met Receptor Kinase and Induces Apoptosis in Diffuse Large B-Cell Lymphoma. Molecular Cancer Therapeutics. 9(5). 1244–1255. 40 indexed citations

Ghebeh, Hazem, Siti‐Faujiah Hendrayani, Asma Tulbah, et al.. (2008). Breast Carcinoma–Associated Fibroblasts and Their Counterparts Display Neoplastic-Specific Changes. Cancer Research. 68(8). 2717–2725. 123 indexed citations

10.

Bazarbashi, Shouki, Mahmoud Abdelsalam, Tarek Amin, et al.. (2008). Phase II Trial of Neoadjuvant Cisplatin, 5-Fluorouracil and Interferon-Alpha in Operable Squamous Cell Carcinoma of the Esophagus. Chemotherapy. 54(4). 315–322. 5 indexed citations

11.

Uddin, Shahab, Azhar Hussain, Maqbool Ahmed, et al.. (2008). S‐phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B‐cell lymphoma. The Journal of Pathology. 216(4). 483–494. 21 indexed citations

12.

Ibrahim, Ezzeldin M., et al.. (2005). Adjuvant Chemotherapy in 780 Patients with Early Breast Cancer: 10-Year Data from Saudi Arabia. Medical Oncology. 22(4). 343–352. 11 indexed citations

13.

Ezzat, Adnan, Ezzeldin M. Ibrahim, Dahish Ajarim, et al.. (2004). Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients. British Journal of Cancer. 90(5). 968–974. 33 indexed citations

14.

Khafaga, Yasser, et al.. (2001). Primary intestinal diffuse large B-cell non-Hodgkin's lymphoma: Clinical features, management, and prognosis of 66 patients. Annals of Oncology. 12(1). 53–58. 67 indexed citations

15.

Allam, Ayman, Alaa Kandil, Gamal El-Husseiny, et al.. (2001). Primary Thyroid Lymphoma. American Journal of Clinical Oncology. 24(3). 299–305. 43 indexed citations

16.

Ezzat, Adnan, Ezzeldin M. Ibrahim, Robert K. Stuart, et al.. (2000). Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial. Medical Oncology. 17(1). 39–46. 10 indexed citations

17.

Raja, M.A., Mohamed Rahal, Dahish Ajarim, et al.. (1999). Primary gastric non-Hodgkin's lymphoma: Clinical features, management, and prognosis of 185 patients with diffuse large B-cell lymphoma. Annals of Oncology. 10(12). 1441–1449. 17 indexed citations

18.

Ibrahim, Ezzeldin M., Fatma A. Al-Mulhim, Ali Al Bshabshe, et al.. (1998). Breast cancer in the eastern province of Saudi Arabia. Medical Oncology. 15(4). 241–247. 39 indexed citations

19.

Santhosh‐Kumar, C.R., et al.. (1992). Ceftazidime and amikacin as empiric treatment of febrile episodes in neutropenic patients in Saudi Arabia. Journal of Infection. 25(1). 11–19. 8 indexed citations

20.

Ajarim, Dahish, et al.. (1991). Bilateral angiosarcoma of the breast. Surgery Today. 21(6). 693–695. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact